PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
34.37%
Net income growth similar to TRAW's 31.33%. Walter Schloss would find parallel expansions or market conditions in both firms’ profitability.
0.63%
Some D&A expansion while TRAW is negative at -1.27%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-79.79%
Both cut yoy SBC, with TRAW at -95.77%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-121.40%
Negative yoy working capital usage while TRAW is 30.83%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-200.00%
Both negative yoy AP, with TRAW at -1345.70%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-91.42%
Negative yoy usage while TRAW is 273.10%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
2.52%
Some yoy increase while TRAW is negative at -264.04%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-18.12%
Both yoy CFO lines are negative, with TRAW at -1.17%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
100.00%
CapEx growth well above TRAW's 50.00%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Investing outflow well above TRAW's 50.00%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy issuance while TRAW is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.